Jenne Kyle's Form 4 filing
Ionis Pharmaceuticals Inc (IONS) · filed Jan 20, 2026
- Accession no.
- 0000874015-26-000066
- Filed
- Jan 20, 2026
- Trade date
- Jan 15-16, 2026
- Filing delay
- 5 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions and 3 derivative transactions. Open-market sales total $138.5K. It was filed 5 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Jenne KyleCIK 0001791857 | Officer (EVP, Chf GL Pdt Str Ofcr) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 15, 2026 | Common Stock | MOption exerciseAcquired | +7,013 | $0.00 | $0 | 18,212 | Direct | |
| Jan 16, 2026 | Common Stock | SSaleDisposed | −1,823 | $75.96F3 | −$138,475.08 | 16,389 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 15, 2026 | Common Stock | AGrant or awardAcquired | +25,800 | $0.00 | $0 | 44,500 | Direct | |
| Jan 15, 2026 | Common Stock | AGrant or awardAcquired | +9,675 | $0.00 | $0 | 37,725 | Direct | |
| Jan 15, 2026 | Common Stock | MOption exerciseDisposed | −7,013 | $0.00 | $0 | 29,664 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F3
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.96 to $75.97 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4.
Referenced by the price of 1 transaction in Table I.